
Peter O'Leary

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2095629/publications.pdf Version: 2024-02-01



DETED O'LEADY

#	Article	lF	CITATIONS
1	Subclinical Thyroid Dysfunction as a Risk Factor for Cardiovascular Disease. Archives of Internal Medicine, 2005, 165, 2467.	3.8	436
2	Decreased Epinephrine Responses to Hypoglycemia during Sleep. New England Journal of Medicine, 1998, 338, 1657-1662.	27.0	275
3	Longitudinal assessment of changes in reproductive hormones during normal pregnancy. Clinical Chemistry, 1991, 37, 667-672.	3.2	220
4	Familial hypercholesterolaemia: A model of care for Australasia. Atherosclerosis Supplements, 2011, 12, 221-263.	1.2	181
5	Thyrotropin and Thyroid Antibodies as Predictors of Hypothyroidism: A 13-Year, Longitudinal Study of a Community-Based Cohort Using Current Immunoassay Techniques. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1095-1104.	3.6	179
6	Identification of Novel Genetic Loci Associated with Thyroid Peroxidase Antibodies and Clinical Thyroid Disease. PLoS Genetics, 2014, 10, e1004123.	3.5	150
7	Cascade screening based on genetic testing is cost-effective: Evidence for the implementation of models of care for familial hypercholesterolemia. Journal of Clinical Lipidology, 2014, 8, 390-400.	1.5	149
8	Investigations of thyroid hormones and antibodies based on a community health survey: the Busselton thyroid study. Clinical Endocrinology, 2006, 64, 97-104.	2.4	136
9	Thyroid dysfunction and serum lipids: a community-based study. Clinical Endocrinology, 2005, 63, 670-675.	2.4	117
10	Subclinical thyroid dysfunction and blood pressure: a community-based study. Clinical Endocrinology, 2006, 65, 486-491.	2.4	99
11	Early Loss of the Glucagon Response to Hypoglycemia in Adolescents With Type 1 Diabetes. Diabetes Care, 2012, 35, 1757-1762.	8.6	96
12	Significant inverse relationship between serum free T4 concentration and body mass index in euthyroid subjects: differences between smokers and nonsmokers. Clinical Endocrinology, 2008, 69, 648-652.	2.4	75
13	Subcutaneous glucose sensor values closely parallel blood glucose during insulin-induced hypoglycaemia. Diabetic Medicine, 2003, 20, 238-241.	2.3	73
14	Evaluating Genetic Counseling: Client Expectations, Psychological Adjustment and Satisfaction with Service. Journal of Genetic Counseling, 2005, 14, 197-206.	1.6	66
15	Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: An Australian experience. Atherosclerosis, 2015, 239, 93-100.	0.8	65
16	Parity and the Risk of Autoimmune Thyroid Disease: A Community-Based Study. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5309-5312.	3.6	63
17	Increasing Incidence of Colorectal Cancer in Adolescents and Young Adults Aged 15–39 Years in Western Australia 1982–2007: Examination of Colonoscopy History. Frontiers in Public Health, 2017, 5, 179.	2.7	60
18	Socio-demographic disparities in the uptake of prenatal screening and diagnosis in Western Australia. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2011, 51, 9-16.	1.0	54

#	Article	IF	CITATIONS
19	Prenatal screening for Down syndrome in Australia: Costs and benefits of current and novel screening strategies. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2013, 53, 425-433.	1.0	51
20	Economic evaluation of neonatal screening for phenylketonuria and congenital hypothyroidism. Journal of Paediatrics and Child Health, 2005, 41, 575-579.	0.8	45
21	Significant association between thyroid hormones and erythrocyte indices in euthyroid subjects. Clinical Endocrinology, 2012, 76, 304-311.	2.4	44
22	First-Trimester Combined Screening for Down Syndrome and Other Fetal Anomalies. Obstetrics and Gynecology, 2006, 107, 869-876.	2.4	39
23	Impact of prenatal screening and diagnostic testing on trends in Down syndrome births and terminations in Western Australia 1980 to 2013. Prenatal Diagnosis, 2015, 35, 1324-1330.	2.3	37
24	Blueprint for a deliberative public forum on biobanking policy: were theoretical principles achievable in practice?. Health Expectations, 2013, 16, 211-224.	2.6	36
25	The log <scp>TSH</scp> –free T4 relationship in a communityâ€based cohort is nonlinear and is influenced by age, smoking and thyroid peroxidase antibody status. Clinical Endocrinology, 2016, 85, 789-796.	2.4	36
26	Survey of the knowledge, attitudes and experiences of Western Australian women in relation to prenatal screening and diagnostic procedures. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2003, 43, 134-138.	1.0	34
27	Regional variations in prenatal screening across Australia: Stepping towards a national policy framework. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2006, 46, 427-432.	1.0	34
28	First trimester predictors of adverse pregnancy outcomes. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2008, 48, 529-535.	1.0	33
29	A modular approach to disease registry design: Successful adoption of an internet-based rare disease registry. Human Mutation, 2012, 33, E2356-E2366.	2.5	31
30	The Impact of Antenatal Screening for Down Syndrome in Western Australia: 1980–1994. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1996, 36, 385-388.	1.0	30
31	Spontaneous regression of <scp>CIN</scp> 2 in women aged 18–24 years: a retrospective study of a stateâ€wide population in Western Australia. Acta Obstetricia Et Gynecologica Scandinavica, 2016, 95, 291-298.	2.8	30
32	Distribution and metabolism of topically applied progesterone in a rat model. Journal of Steroid Biochemistry and Molecular Biology, 2002, 80, 449-455.	2.5	27
33	Salivary, but not serum or urinary levels of progesterone are elevated after topical application of progesterone cream to pre-and postmenopausal women. Clinical Endocrinology, 2000, 53, 615-620.	2.4	26
34	An Australian Approach to the Policy Translation of Deliberated Citizen Perspectives on Biobanking. Public Health Genomics, 2012, 15, 82-91.	1.0	26
35	Familial hypercholesterolaemia: a review with emphasis on evidence for treatment, new models of care and health economic evaluations. International Journal of Evidence-Based Healthcare, 2012, 10, 211-221.	0.5	25
36	Longitudinal study of serum thyroid hormone levels during normal pregnancy. International Journal of Gynecology and Obstetrics, 1992, 38, 171-179.	2.3	23

#	Article	IF	CITATIONS
37	A New Model of Care for Familial Hypercholesterolaemia from Western Australia: Closing a Major Gap in Preventive Cardiology. Heart Lung and Circulation, 2010, 19, 419-422.	0.4	22
38	The impact of single gene and chromosomal disorders on hospital admissions in an adult population. Journal of Community Genetics, 2011, 2, 81-90.	1.2	22
39	Comparison of cold knife cone biopsy and loop electrosurgical excision procedure in the management of cervical adenocarcinoma in situ: What is the gold standard?. Gynecologic Oncology, 2015, 137, 258-263.	1.4	22
40	Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 10-21.	2.5	22
41	Perceptions of Population Cystic Fibrosis Prenatal and Preconception Carrier Screening Among Individuals with Cystic Fibrosis and Their Family Members. Genetic Testing and Molecular Biomarkers, 2011, 15, 159-164.	0.7	21
42	Assessment of Breast Milk Iodine Concentrations in Lactating Women in Western Australia. Nutrients, 2016, 8, 699.	4.1	21
43	Factors influencing neonatal thyroid-stimulating hormone concentrations as a measure of population iodine status. Journal of Pediatric Endocrinology and Metabolism, 2014, 27, 101-6.	0.9	18
44	Serum Progesterone and Human Chorionic Gonadotrophin Measurements in the Evaluation of Ectopic Pregnancy. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1996, 36, 319-323.	1.0	17
45	Communicating Familial Hypercholesterolemia Genetic Information Within Families. Genetic Testing and Molecular Biomarkers, 2009, 13, 301-306.	0.7	17
46	Increasing use of CT requested by emergency department physicians in tertiary hospitals in Western Australia 2003–2015: an analysis of linked administrative data. BMJ Open, 2021, 11, e043315.	1.9	17
47	Folate status in Aboriginal people before and after mandatory fortification of flour for bread-making in Australia. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2016, 56, 233-237.	1.0	16
48	Elevated mid-trimester hCG and maternal lupus anticoagulant. Prenatal Diagnosis, 1995, 15, 1035-1039.	2.3	15
49	Human Genetics Society of Australasia Position Statement: Population-Based Carrier Screening for Cystic Fibrosis. Twin Research and Human Genetics, 2014, 17, 578-583.	0.6	15
50	The potential impact of <scp>NIPT</scp> as a secondâ€ŧier screen on the outcomes of highâ€ŧisk pregnancies with rare chromosomal abnormalities. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2015, 55, 420-426.	1.0	13
51	The Australian primary healthcare experiment: a national survey of Medicare Locals. BMJ Open, 2015, 5, e007191-e007191.	1.9	13
52	Informing policy for the Australian context – Costs, outcomes and cost savings of prenatal carrier screening for cystic fibrosis. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2010, 50, 51-59.	1.0	12
53	Risk of persistent and recurrent cervical neoplasia following incidentally detected adenocarcinoma in situ. American Journal of Obstetrics and Gynecology, 2017, 216, 272.e1-272.e7.	1.3	12
54	Combining first and second trimester markers for Down syndrome screening: Think twice. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2008, 48, 492-500.	1.0	11

#	Article	IF	CITATIONS
55	Diagnostic performance and costs of contingent screening models for trisomy 21 incorporating nonâ€invasive prenatal testing. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2017, 57, 432-439.	1.0	11
56	Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1737-1744.	2.8	11
57	Communication of Genetic Information within Families: The Case for Familial Comity. Journal of Bioethical Inquiry, 2006, 3, 161-166.	1.5	10
58	Community attitudes to the collection and use of identifiable data for health research – is it an invasion of privacy?. Australian and New Zealand Journal of Public Health, 2007, 31, 313-317.	1.8	10
59	Informing Public Health Policy Through Deliberative Public Engagement: Perceived Impact on Participants and Citizen–Government Relations. Genetic Testing and Molecular Biomarkers, 2013, 17, 713-718.	0.7	10
60	Public funding for nonâ€invasive prenatal testing for fetal aneuploidy – It's time. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2018, 58, 385-387.	1.0	10
61	Motivating intentions to adopt risk-reducing behaviours for chronic diseases: Impact of a public health tool for collecting family health histories. Health Promotion Journal of Australia, 2011, 22, 57-62.	1.2	9
62	Newborn bloodspot screening policy framework for Australia. Australasian Medical Journal, 2015, 8, 292-298.	0.1	9
63	A survey of folate knowledge and consumer behaviours in Western Australia prior to the introduction of mandatory food fortification. Australian and New Zealand Journal of Public Health, 2009, 33, 577-582.	1.8	8
64	Baseline investigations of folate status in <scp>A</scp> boriginal and nonâ€ <scp>A</scp> boriginal <scp>W</scp> est <scp>A</scp> ustralians prior to the introduction of mandatory fortification. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2013, 53, 26-31.	1.0	8
65	Women's Understanding and Attitudes towards Down Syndrome and Other Genetic Conditions in the Context of Prenatal Screening. Journal of Genetic Counseling, 2018, 27, 647-655.	1.6	8
66	Newborn bloodspot screening: setting the Australian national policy agenda. Medical Journal of Australia, 2014, 200, 142-143.	1.7	7
67	The increase in cancer prevalence and hospital burden in Western Australia, 1992–2011. Population Health Metrics, 2014, 12, 33.	2.7	7
68	Prenatal screening and diagnosis: A survey of health care providers' knowledge and attitudes. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2003, 43, 307-311.	1.0	6
69	Cost-effectiveness of predictive genetic tests for familial breast and ovarian cancer. Genomics Society and Policy, 2005, 1, 1.	0.2	6
70	Genomics and Public Health: Translating Research into Public Benefit. Public Health Genomics, 2010, 13, 193-196.	1.0	6
71	Familial and non-familial risk factors associated with incidence of colorectal cancer in young and middle-aged persons in Western Australia. Cancer Epidemiology, 2019, 62, 101591.	1.9	6
72	Compliance with professional guidelines with reference to familial cancer services. Australian and New Zealand Journal of Public Health, 2011, 35, 226-230.	1.8	5

#	Article	IF	CITATIONS
73	How have advances in CT dosimetry software impacted estimates of CT radiation dose and cancer incidence? A comparison of CT dosimetry software: Implications for past and future research. PLoS ONE, 2019, 14, e0217816.	2.5	5
74	Australian survey on community knowledge and attitudes regarding the fortification of food with folic acid. Birth Defects Research Part A: Clinical and Molecular Teratology, 2007, 79, 664-670.	1.6	4
75	Risk of highâ€grade cervical dysplasia and gynaecological malignancies following the cytologic diagnosis of atypical endocervical cells of undetermined significance: A retrospective study of a stateâ€wide screening population in Western Australia. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2015, 55, 268-273.	1.0	4
76	First trimester screening cutâ€offs for noninvasive prenatal testing as a contingent screen: Balancing detection and screenâ€positive rates for trisomy 21. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2016, 56, 29-35.	1.0	4
77	The human papillomavirus Test of Cure: A lesson on compliance with the NHMRC guidelines on screening to prevent cervical cancer. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2015, 55, 185-190.	1.0	3
78	Knowledge of nonâ€invasive prenatal testing among pregnant women. Medical Journal of Australia, 2015, 203, 76-76.	1.7	3
79	Integrating personalised genomics into risk stratification models of population screening for colorectal cancer. Australian and New Zealand Journal of Public Health, 2017, 41, 3-4.	1.8	3
80	Optimizing Patient Risk Stratification for Colonoscopy Screening and Surveillance of Colorectal Cancer: The Role for Linked Data. Frontiers in Public Health, 2017, 5, 234.	2.7	3
81	Plenty of evidence on mandatory folate fortification. Australian and New Zealand Journal of Public Health, 2006, 30, 81-82.	1.8	2
82	The Western Australian Family Connections Genealogical Project: Detection of Familial Occurrences of Single Gene and Chromosomal Disorders. Genetic Testing and Molecular Biomarkers, 2014, 18, 77-82.	0.7	2
83	A framework for bridging the gap in the care of familial hypercholesterolaemia in the community. International Journal of Evidence-Based Healthcare, 2014, 12, 244-254.	O.5	2
84	Screening for Down syndrome in the second trimester of pregnancy. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2016, 56, 19-21.	1.0	2
85	What Is the Good of It—Ethical Controls of Human Subject Health Research?. Journal of Bioethical Inquiry, 2018, 15, 589-602.	1.5	2
86	Familial and non-familial risk factors associated with colorectal cancer survival in young and middle-aged patients. International Journal of Colorectal Disease, 2019, 34, 1673-1680.	2.2	2
87	The Disclosure of Genetic Information: A Human Research Ethics Perspective. Journal of Bioethical Inquiry, 2010, 7, 103-109.	1.5	1
88	The use of computed tomography in the management of injury in tertiary emergency departments in Western Australia: Evidence of overâ€ŧesting?. Academic Emergency Medicine, 2021, , .	1.8	1
89	Factors driving CT utilisation in tertiary hospitals: a decomposition analysis using linked administrative data in Western Australia. BMJ Open, 2021, 11, e052954.	1.9	1